McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “End of the Road in Sight for Myriad” that appears in the online edition of Pharmaceutical Compliance Monitor on May 14, 2013. The Supreme Court heard oral argument in the AMP v. Myriad Genetics case on April 15, 2013, marking the penultimate step in the long journey that began in 2009, and will result in a decision sometime before the end of June regarding the patent eligibility of isolated human DNA. Although the impact of this decision on DNA patenting will be cabined by a number of factors not considered by the Court, there is the possibility of far-reaching, negative ramifications should the Justices issue a broad product-of-nature exception to the general rule that “anything under the sun made by man” is eligible for patenting. View the article
